Vaccination against heterologous R5 clade C SHIV: Prevention of infection and correlates of protection

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Lakhashe, Samir K ^a,b   Wang, Wendy ^a   Siddappa, Nagadenahalli B ^a,b   Hemashettar, Girish ^a   Polacino, Patricia ^c   Hu, Shiu Lok ^c   Villinger, François ^d,e   Else, James G ^d,e   Novembre, Francis J ^d,e   Yoon, John K ^a   Lee, Sandra J ^a,b   Montefiori, David C ^f   Ruprecht, Ruth M ^a,b   Rasmussen, Robert A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EMORY UNIVERSITY   (United States)

^f DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 160; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; GP160 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; RECOMBINANT VACCINE; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMORAL IMMUNITY; IMMUNOGENICITY; NONHUMAN; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS STRAIN; ANIMAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INFANT; MACACA MULATTA; METHODOLOGY; VACCINATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; FUSION PROTEINS, GAG-POL; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES; VIREMIA;

EID: 79960561410     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022010     Document Type: Article

References (50)

1. Buchbinder SP, (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
2. McElrath MJ, (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
3. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
4. Koup RA, Graham BS, Douek DC, (2010) The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol 11: 65-70.
5. McElrath MJ, Haynes BF, (2010) Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33: 542-554.
6. Lu Y, Pauza CD, Lu X, Montefiori DC, Miller CJ, (1998) Rhesus macaques that become systemically infected with pathogenic SHIV 89.6-PD after intravenous, rectal, or vaginal inoculation and fail to make an antiviral antibody response rapidly develop AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 19: 6-18.
7. Nishimura Y, Igarashi T, Donau OK, Buckler-White A, Buckler C, et al. (2004) Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci U S A 101: 12324-12329.
8. Pope M, Haase AT, (2003) Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9: 847-852.
9. Vlasak J, Ruprecht RM, (2006) AIDS vaccine development and challenge viruses: getting real. AIDS 20: 2135-2140.
10. Song RJ, Chenine AL, Rasmussen RA, Ruprecht CR, Mirshahidi S, et al. (2006) Molecularly cloned SHIV-1157ipd3N4: a highly replication- competent, mucosally transmissible R5 simian-human immunodeficiency virus encoding HIV clade C Env. J Virol 80: 8729-8738.
11. Siddappa NB, Song R, Kramer VG, Chenine AL, Velu V, et al. (2009) Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol 83: 1422-1432.
12. Siddappa NB, Watkins JD, Wassermann KJ, Song R, Wang W, et al. (2010) R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS One 5: e11689.
13. Chenine AL, Siddappa NB, Kramer VG, Sciaranghella G, Rasmussen RA, et al. (2010) Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J Infect Dis 201: 1155-1163.
14. Humbert M, Rasmussen RA, Song R, Ong H, Sharma P, et al. (2008) SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology 5: 94.
15. Montano MA, Nixon CP, Ndung'u T, Bussmann H, Novitsky VA, et al. (2000) Elevated tumor necrosis factor-alpha activation of human immunodeficiency virus type 1 subtype C in Southern Africa is associated with an NF-kappaB enhancer gain-of-function. J Infect Dis 181: 76-81.
16. Lin J, Calcedo R, Vandenberghe LH, Figueredo JM, Wilson JM, (2008) Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines. Hum Gene Ther 19: 663-669.
17. D'Souza MP, Frahm N, (2010) Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 24: 803-809.
18. Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, et al. (2009) Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A 106: 19940-19945.
19. Perreau M, Pantaleo G, Kremer EJ, (2008) Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 205: 2717-2725.
20. Villadangos JA, Shortman K, (2010) Found in translation: the human equivalent of mouse CD8+ dendritic cells. J Exp Med 207: 1131-1134.
21. Grisson RD, Chenine AL, Yeh LY, He J, Wood C, et al. (2004) Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination. J Virol 78: 14066-14069.
22. Balfe P, Shapiro S, Hsu M, Buckner C, Harouse JM, et al. (2004) Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques. Virology 318: 267-279.
23. Letvin NL, Mascola JR, Sun Y, Gorgone DA, Buzby AP, et al. (2006) Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312: 1530-1533.
24. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, et al. (2009) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457: 87-91.
25. Hofmann-Lehmann R, Swenerton RK, Liska V, Leutenegger CM, Lutz H, et al. (2000) Sensitive and robust one-tube real-time reverse transcriptase-polymerase chain reaction to quantify SIV RNA load: comparison of one- versus two-enzyme systems. AIDS Res Hum Retroviruses 16: 1247-1257.
26. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, et al. (2000) Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290: 486-492.
27. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
28. Hladik F, McElrath MJ, (2008) Setting the stage: host invasion by HIV. Nat Rev Immunol 8: 447-457.
29. Derdeyn CA, Decker JM, Bibollet-Ruche F, Mokili JL, Muldoon M, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019-2022.
30. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, et al. (2006) Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80: 11776-11790.
31. Dreja H, O'Sullivan E, Pade C, Greene KM, Gao H, et al. (2010) Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. J Gen Virol 91: 2794-2803.
32. Forsell MN, Schief WR, Wyatt RT, (2009) Immunogenicity of HIV-1 envelope glycoprotein oligomers. Curr Opin HIV AIDS 4: 380-387.
33. Barnett SW, Srivastava IK, Kan E, Zhou F, Goodsell A, et al. (2008) Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22: 339-348.
34. Mann AM, Rusert P, Berlinger L, Kuster H, Gunthard HF, et al. (2009) HIV sensitivity to neutralization is determined by target and virus producer cell properties. AIDS 23: 1659-1667.
35. Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, et al. (2008) Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375: 315-320.
36. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, et al. (2009) Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 182: 3718-3727.
37. Forthal DN, Moog C, (2009) Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS 4: 388-393.
38. Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, et al. (2010) Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 84: 7161-7173.
39. Bomsel M, (2011) Mucosal antibodies induced by immunization with HIV-1 gp41-subunit virosomes provide protection against vaginal SHIV challenges in non-human primates. Immunity In press.
40. Hladik F, Hope TJ, (2009) HIV infection of the genital mucosa in women. Curr HIV/AIDS Rep 6: 20-28.
41. Koopman G, Mortier D, Hofman S, Mathy N, Koutsoukos M, et al. (2008) Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J Gen Virol 89: 540-553.
42. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789.
43. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, et al. (2008) Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 38: 350-363.
44. Rasmussen RA, Ong H, Kittel C, Ruprecht CR, Ferrantelli F, et al. (2006) DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice. Vaccine 24: 2324-2332.
45. Rasmussen RA, Ong H, Song R, Chenine AL, Ayash-Rashkovsky M, et al. (2007) Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges. Aids 21: 1841-1848.
46. Cline AN, Bess JW, Piatak M Jr, Lifson JD, (2005) Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J Med Primatol 34: 303-312.
47. Saitou N, Nei M, (1987) The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4: 406-425.
48. Tamura K, Dudley J, Nei M, Kumar S, (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 24: 1596-1599.
49. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, et al. (2007) HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci U S A 104: 6776-6781.
50. Sacha JB, Giraldo-Vela JP, Buechler MB, Martins MA, Maness NJ, et al. (2009) Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc Natl Acad Sci U S A 106: 9791-9796.